Company Profile
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company develops drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. It also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction
MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer. It has a strategic partnership with Eyenovia, Inc. for the development of novel ophthalmic therapeutic Singapore Eye Research Institute to develop ophthalmic formulations for corneal diseases. Founded in 2010, Formosa Pharmaceuticals is headquartered in Taipei City, Taiwan.